These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7199587)

  • 41. Effects of flutamide on pituitary and adrenal responsiveness to corticotrophin releasing factor (CRF).
    De Leo V; la Marca A; Lanzetta D; Cariello PL; D'Antona D; Morgante G
    Clin Endocrinol (Oxf); 1998 Jul; 49(1):85-9. PubMed ID: 9797851
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hirsutism.
    Morris DV
    Clin Obstet Gynaecol; 1985 Sep; 12(3):649-74. PubMed ID: 3905161
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spironolactone for hirsutism in polycystic ovary syndrome.
    Christy NA; Franks AS; Cross LB
    Ann Pharmacother; 2005 Sep; 39(9):1517-21. PubMed ID: 16076921
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical and biochemical evaluation of patients with hirsutism.
    Holdaway IM; Croxson MS; Frengley PA; Ibbertson HK; Sheehan A; Fraser A; Evans MC; Knox BS; France JT; Graham FM
    Aust N Z J Obstet Gynaecol; 1984 Feb; 24(1):23-9. PubMed ID: 6234877
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The influence of combined cyproterone acetate-ethinyl oestradiol therapy on serum levels of dehydroepiandrosterone, androstenedione, and testosterone in hirsute women.
    Frölich M; Lachinsky N; Moolenaar AJ
    Acta Endocrinol (Copenh); 1977 Feb; 84(2):333-42. PubMed ID: 138326
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Testosterone, 17 Ks, 17 beta E2 FSH-LH variations and hirsutism modifications during spironolactone therapy.
    Spandri P; Gangemi M; Nardelli GB; Meneghetti G; Grandesso R; De Salvia D; Ambrosio GB; Predebon O
    Clin Exp Obstet Gynecol; 1984; 11(1-2):49-54. PubMed ID: 6424970
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial.
    Moghetti P; Tosi F; Tosti A; Negri C; Misciali C; Perrone F; Caputo M; Muggeo M; Castello R
    J Clin Endocrinol Metab; 2000 Jan; 85(1):89-94. PubMed ID: 10634370
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of low-dose GnRH analogue (Buserelin) in the treatment of hirsutism.
    Bertoli A; Fusco A; Magnani A; Marini MA; Di Daniele N; Gatti S; Lauro R
    Exp Clin Endocrinol Diabetes; 1995; 103(1):15-20. PubMed ID: 7621099
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women.
    Lobo RA; Shoupe D; Serafini P; Brinton D; Horton R
    Fertil Steril; 1985 Feb; 43(2):200-5. PubMed ID: 3967781
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
    Brown J; Farquhar C; Lee O; Toomath R; Jepson RG
    Cochrane Database Syst Rev; 2009 Apr; (2):CD000194. PubMed ID: 19370553
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Medical treatment regimens of hirsutism.
    Sahin Y; Kelestimur F
    Reprod Biomed Online; 2004 May; 8(5):538-46. PubMed ID: 15151716
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism.
    Keleştimur F; Everest H; Unlühizarci K; Bayram F; Sahin Y
    Eur J Endocrinol; 2004 Mar; 150(3):351-4. PubMed ID: 15012621
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Determination of the source(s) of androgen overproduction in hirsutism associated with polycystic ovary syndrome by simultaneous adrenal and ovarian venous catheterization. Comparison with the dexamethasone suppression test.
    Wajchenberg BL; Achando SS; Okada H; Czeresnia CE; Peixoto S; Lima SS; Goldman J
    J Clin Endocrinol Metab; 1986 Nov; 63(5):1204-10. PubMed ID: 3760120
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 17-Hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities.
    Maier PS; Mattiello SS; Lages L; Spritzer PM
    Gynecol Endocrinol; 2012 Aug; 28(8):606-10. PubMed ID: 22329763
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of hirsutism in women with flutamide.
    Marcondes JA; Minnani SL; Luthold WW; Wajchenberg BL; Samojlik E; Kirschner MA
    Fertil Steril; 1992 Mar; 57(3):543-7. PubMed ID: 1531466
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
    Farquhar C; Lee O; Toomath R; Jepson R
    Cochrane Database Syst Rev; 2003; (4):CD000194. PubMed ID: 14583916
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hair growth and androgen responses in hirsute women treated with continuous cyproterone acetate and cyclical ethinyl oestradiol.
    Jones DB; Ibraham I; Edwards CR
    Acta Endocrinol (Copenh); 1987 Dec; 116(4):497-501. PubMed ID: 2962412
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of the combination spironolactone-norgestimate-estrogen in Hirsute women with polycystic ovary syndrome.
    Hagag P; Steinschneider M; Weiss M
    J Reprod Med; 2014; 59(9-10):455-63. PubMed ID: 25330687
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic effects of spironolactone in polycystic ovary syndrome.
    Milewicz A; Silber D; Kirschner MA
    Obstet Gynecol; 1983 Apr; 61(4):429-32. PubMed ID: 6828272
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hirsutism - from diagnosis to use of antiandrogens.
    Unluhizarci K; Karaca Z; Kelestimur F
    Front Horm Res; 2013; 40():103-14. PubMed ID: 24002408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.